Holen Sie sich die Stockscreener-App
15.57
2.35%
-0.3706
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com Canada
Contineum (CTNM) CEO sells shares under preset plan - Stock Titan
Carmine Stengone to sell 2,500 Contineum (CTNM) shares - Stock Titan
Technical Reactions to CTNM Trends in Macro Strategies - news.stocktradersdaily.com
Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs - RTTNews
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportWyckoff Accumulation - vinanet.vn
Officer at Contineum (NASDAQ: CTNM) lines up new stock sale - Stock Titan
Behavioral Patterns of CTNM and Institutional Flows - news.stocktradersdaily.com
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - qz.com
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - The Chronicle-Journal
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session - vinanet.vn
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session; Chart View: the Current Price Sits Inside the Supplied Technical Range in the Available RecordVolatility Breakout Picks - siam.in
Balyasny Asset Management L.P. Expands Stake in Contineum Therap - GuruFocus
Contineum (CTNM) Results at a Glance: The Bottom-Line Figure Beats Its Comparison in Latest Trading; Closing Move - vinanet.vn
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - marketscreener.com
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $23.14, Implies 63% Upside - TradingView
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says - Yahoo Finance
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffFair Value Gap - vinanet.vn
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - MarketBeat
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Share GainCFO Commentary Report - Vinanet
CTNM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - Vinanet
Contineum Therapeutics (CTNM) Pulls Back 3.66% to $14.49 as Support Level Comes into FocusComposite Profile - vinanet.vn
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 2,500 shares after option exercise - Stock Titan
CTNM (CTNM) insider schedules 2,500-share stock sale after recent 10b5-1 trades - Stock Titan
CTNM (CTNM) insider Daniel Lorrain files to sell 9,520 common shares - Stock Titan
Contineum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM - MarketBeat
RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
Contineum Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Contineum reports $15.2 million second quarter loss - Quiver Quantitative
Contineum Therapeutics reports Q2 2026 net loss $15.2M; cash and marketable securities $236.6M - TradingView
Contineum Therapeutics, Inc. Revenue Breakdown – NASDAQ:CTNM - TradingView
BlackRock (CTNM stakeholder) reports 2.0M-share beneficial position in Therapeutics Inc - Stock Titan
CTNM|Contineum Therapeutics Inc|Price:15.390|Chg%:-0.510 - TradingKey
Contineum Therapeutics Inc (CTNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Contineum Therapeutics Inc (CTNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Contineum Therapeutics Inc (CTNM) Institutional Confidence - TradingKey
Contineum Therapeutics Inc (CTNM) Balance Sheet - TradingKey
Contineum Therapeutics Market Sentiment - Benzinga España
TradingKey - TradingKey
Contineum Therapeutics Inc (CTNM) Income Statement - TradingKey
CTNM|Contineum Therapeutics Inc|Price:13.835|Chg%:-0.225 - TradingKey
CTNM|Contineum Therapeutics Inc|Price:14.060|Chg%:-0.310 - TradingKey
Millennium Management LLC Reduces Stake in Contineum Therapeutics Inc - GuruFocus
Contineum Therapeutics Inc. (CTNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise, Stock Pulls BackEPS Growth Rate - dars.gov.et
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ: CTNM) Stock Price, News & Analysis - Kalkine
Liquidity Mapping Around (CTNM) Price Events - Stock Traders Daily
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):